Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effecti ...

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

The usage of tenecteplase in patients with acute ischemic stroke was associated with similar effectiveness and safety ...

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to ...

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a decades-old medication used by most hospitals in the U.S. and could hold ...

Background: Tenecteplase improves functional outcomes in acute ischemic stroke (AIS) patients treated 4.5 to 24 h after symptom onset who do not undergo thrombectomy. However, its cost-utility remains ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a ...

This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a 60-minute infusion. Genentech, the manufacturer of TNKase ...

The drug is administered as a single, 5-second intravenous bolus — a faster and simpler administration compared to the standard of care 60-minute infusion of alteplase (Activase; Genentech), the ...